Covered recipient · General Payments record
JOHN NIVEN
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$30.02
2 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $30.02 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| LEO Pharma Inc. | $15.04 | 1 |
| Lilly USA, LLC | $14.98 | 1 |
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN NIVEN
NPI 1336167634 · CMS profile ID 60481
Allopathic & Osteopathic Physicians / Dermatology
MIAMI BEACH, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1336167634?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN NIVEN, NPI 1336167634, CMS profile ID 60481. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336167634?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). JOHN NIVEN, NPI 1336167634, CMS profile ID 60481. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336167634?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- JOHN NIVEN, NPI 1336167634, CMS profile ID 60481, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1336167634?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
2 matching records · $30.02 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–2 of 2.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $14.98 | 08/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657897231 | CMS |
| LEO Pharma Inc. | $15.04 | 06/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687268449 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020
- Generated from
- OP_DTL_GNRL_PGYR2020_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $547,115.16 | 88 |
| PY2024 | Principal investigator | $919,823.31 | 487 |
| PY2023 | Recipient | $1,200.00 | 1 |
| PY2023 | Principal investigator | $635,503.38 | 419 |
| PY2022 | Principal investigator | $475,737.00 | 87 |
| PY2021 | Principal investigator | $161,162.86 | 33 |
| PY2020 | Principal investigator | $161,071.72 | 49 |
| PY2019 | Principal investigator | $202,395.85 | 23 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
87 records in PY2022
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $157.00 | 12/31/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 965540505 |
| Principal investigator 1 | ABBVIE INC. | $3,209.00 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement | No dispute reported | 06/30/2026 | 889825377 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $359.12 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434021 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $359.12 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434023 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $359.12 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434055 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $359.12 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434057 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $359.12 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434059 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $359.12 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434061 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $359.12 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434063 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $359.12 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434065 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,613.72 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434067 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,514.28 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434069 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,514.28 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434071 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,514.28 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434073 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,514.28 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434075 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,217.03 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434077 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,217.03 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434079 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,217.03 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434081 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,217.03 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434083 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,217.03 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434149 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,217.03 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434151 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,217.03 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434153 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,217.03 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434155 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,459.02 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434157 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,459.02 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434159 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,459.02 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434161 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,459.02 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434163 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,459.02 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434165 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,459.02 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434167 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,459.02 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434169 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,459.02 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434171 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,459.02 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | No dispute reported | 06/30/2026 | 937434173 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $262.44 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 937435267 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $262.44 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 937435269 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $262.44 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 937435271 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $262.44 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 937435273 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,177.25 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 937435285 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,177.25 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 937435287 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,177.25 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 937435289 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,177.25 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 937435291 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,217.03 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 937435293 |
| Principal investigator 1 | Dermavant Sciences, Inc. | $1,217.03 | 12/15/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 937435295 |
| Principal investigator 1 | ABBVIE INC. | $16,267.00 | 12/08/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 889823981 |
| Principal investigator 1 | ABBVIE INC. | $3,475.00 | 11/16/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement | No dispute reported | 06/30/2026 | 889820903 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $2,808.18 | 11/11/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) | No dispute reported | 06/30/2026 | 936709223 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $164.92 | 11/09/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) | No dispute reported | 06/30/2026 | 936709129 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $1,323.90 | 11/09/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) | No dispute reported | 06/30/2026 | 936709139 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $1,649.20 | 11/09/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) | No dispute reported | 06/30/2026 | 936709197 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $1,319.36 | 11/09/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) | No dispute reported | 06/30/2026 | 936709206 |
| Principal investigator 1 | ABBVIE INC. | $13,022.20 | 11/08/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 889818271 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $250.00 | 11/07/2022 | Non-covered Recipient Entity Interspond LLC | Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab | No dispute reported | 06/30/2026 | 935664354 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,984.90 | 11/03/2022 | Non-covered Recipient Entity LENUS RESEARCH AND MEDICAL GROUP LLC | Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis | No dispute reported | 06/30/2026 | 961874119 |
| Principal investigator 1 | ABBVIE INC. | $4,680.50 | 10/13/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement | No dispute reported | 06/30/2026 | 889815395 |
| Principal investigator 1 | Almirall LLC | $1,051.88 | 10/11/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICALGROUP, LLC | M14867-32 | No dispute reported | 06/30/2026 | 902933301 |
| Principal investigator 1 | ABBVIE INC. | $5,899.30 | 10/06/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 889813133 |
| Principal investigator 1 | Almirall LLC | $30,499.30 | 09/12/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICALGROUP, LLC | M14867-32 | No dispute reported | 06/30/2026 | 902933247 |
| Principal investigator 1 | GENZYME CORPORATION | $300.00 | 09/12/2022 | Non-covered Recipient Entity Lenus Research Medical Group LLC | Activ-POC - AD - Topical | No dispute reported | 06/30/2026 | 935598449 |
| Principal investigator 1 | ABBVIE INC. | $9,444.25 | 09/08/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 889810803 |
| Principal investigator 1 | ABBVIE INC. | $3,799.00 | 09/08/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement | No dispute reported | 06/30/2026 | 889810805 |
| Principal investigator 1 | ABBVIE INC. | $20,025.40 | 08/31/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 889808017 |
| Principal investigator 1 | ABBVIE INC. | $1,737.50 | 08/16/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement | No dispute reported | 06/30/2026 | 889806279 |
| Principal investigator 1 | Almirall LLC | $16,396.88 | 08/09/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICALGROUP, LLC | M14867-32 | No dispute reported | 06/30/2026 | 902933163 |
| Principal investigator 1 | Almirall LLC | $2,100.00 | 08/09/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICALGROUP, LLC | M14867-32 | No dispute reported | 06/30/2026 | 902933165 |
| Principal investigator 1 | GENZYME CORPORATION | $36,700.00 | 08/08/2022 | Non-covered Recipient Entity Lenus Research Medical Group LLC | Activ-POC - AD - Topical | No dispute reported | 06/30/2026 | 935598323 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $250.00 | 08/08/2022 | Non-covered Recipient Entity Interspond LLC | Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab | No dispute reported | 06/30/2026 | 935663876 |
| Principal investigator 1 | ABBVIE INC. | $4,813.50 | 07/14/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement | No dispute reported | 06/30/2026 | 889800881 |
| Principal investigator 1 | ABBVIE INC. | $15,267.35 | 07/14/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 889800883 |
| Principal investigator 1 | Almirall LLC | $6,443.00 | 06/30/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICALGROUP, LLC | M14867-32 | No dispute reported | 06/30/2026 | 902933105 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $4,452.84 | 06/24/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) | No dispute reported | 06/30/2026 | 936708741 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $1,649.20 | 06/17/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) | No dispute reported | 06/30/2026 | 936708835 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $1,154.44 | 06/17/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) | No dispute reported | 06/30/2026 | 936708845 |
| Principal investigator 1 | ABBVIE INC. | $4,414.50 | 06/16/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement | No dispute reported | 06/30/2026 | 889795547 |
| Principal investigator 1 | ABBVIE INC. | $5,160.90 | 06/16/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 889796103 |
| Principal investigator 1 | GENZYME CORPORATION | $140,600.00 | 06/02/2022 | Non-covered Recipient Entity Lenus Research Medical Group LLC | Activ-POC - AD - Topical | No dispute reported | 06/30/2026 | 935598225 |
| Principal investigator 1 | ABBVIE INC. | $1,471.50 | 05/12/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement | No dispute reported | 06/30/2026 | 889791119 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $250.00 | 05/03/2022 | Non-covered Recipient Entity Interspond LLC | Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab | No dispute reported | 06/30/2026 | 935663174 |
| Principal investigator 1 | ABBVIE INC. | $3,999.00 | 04/14/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement | No dispute reported | 06/30/2026 | 889785871 |
| Principal investigator 1 | GENZYME CORPORATION | $11,600.00 | 04/11/2022 | Non-covered Recipient Entity Lenus Research Medical Group LLC | Activ-POC - AD - Topical | No dispute reported | 06/30/2026 | 935598145 |
| Principal investigator 1 | GENZYME CORPORATION | $1,600.00 | 03/28/2022 | Non-covered Recipient Entity Lenus Research Medical Group LLC | Activ-POC - AD - Topical | No dispute reported | 06/30/2026 | 935598113 |
| Principal investigator 1 | ABBVIE INC. | $13,996.00 | 03/17/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement | No dispute reported | 06/30/2026 | 889782027 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $1,644.66 | 03/16/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) | No dispute reported | 06/30/2026 | 936708721 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $750.00 | 03/14/2022 | Non-covered Recipient Entity Interspond LLC | Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab | No dispute reported | 06/30/2026 | 935663277 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $7,552.08 | 02/23/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) | No dispute reported | 06/30/2026 | 936708713 |
| Principal investigator 1 | ABBVIE INC. | $6,675.50 | 02/16/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement (IMMprint) | No dispute reported | 06/30/2026 | 889777437 |
| Principal investigator 1 | GENZYME CORPORATION | $11,100.00 | 02/07/2022 | Non-covered Recipient Entity Lenus Research Medical Group LLC | Activ-POC - AD - Topical | No dispute reported | 06/30/2026 | 935598065 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $3,811.32 | 01/17/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) | No dispute reported | 06/30/2026 | 936708701 |
| Principal investigator 1 | ABBVIE INC. | $5,212.50 | 01/12/2022 | Non-covered Recipient Entity LENUS RESEARCH & MEDICAL GROUP LLC | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement (IMMprint) | No dispute reported | 06/30/2026 | 889773355 |